Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Nurture trumps nature!

Demissie E, Pillai S.

Sci Immunol. 2017 Apr 7;2(10). pii: eaan2236. doi: 10.1126/sciimmunol.aan2236.

PMID:
28738018
2.

B lymphocytes and cancer: a love-hate relationship.

Yuen GJ, Demissie E, Pillai S.

Trends Cancer. 2016 Dec;2(12):747-757. doi: 10.1016/j.trecan.2016.10.010. Review. No abstract available.

3.

Striking Immune Phenotypes in Gene-Targeted Mice Are Driven by a Copy-Number Variant Originating from a Commercially Available C57BL/6 Strain.

Mahajan VS, Demissie E, Mattoo H, Viswanadham V, Varki A, Morris R, Pillai S.

Cell Rep. 2016 May 31;15(9):1901-9. doi: 10.1016/j.celrep.2016.04.080. Epub 2016 May 19.

4.

Protein Quantitative Trait Loci Analysis Identifies Genetic Variation in the Innate Immune Regulator TOLLIP in Post-Lung Transplant Primary Graft Dysfunction Risk.

Cantu E, Suzuki Y, Diamond JM, Ellis J, Tiwari J, Beduhn B, Nellen JR, Shah R, Meyer NJ, Lederer DJ, Kawut SM, Palmer SM, Snyder LD, Hartwig MG, Lama VN, Bhorade S, Crespo M, Demissie E, Wille K, Orens J, Shah PD, Weinacker A, Weill D, Wilkes D, Roe D, Ware LB, Wang F, Feng R, Christie JD; Lung Transplant Outcomes Group.

Am J Transplant. 2016 Mar;16(3):833-40. doi: 10.1111/ajt.13525. Epub 2015 Dec 10.

5.

Objective Estimates Improve Risk Stratification for Primary Graft Dysfunction after Lung Transplantation.

Shah RJ, Diamond JM, Cantu E, Flesch J, Lee JC, Lederer DJ, Lama VN, Orens J, Weinacker A, Wilkes DS, Roe D, Bhorade S, Wille KM, Ware LB, Palmer SM, Crespo M, Demissie E, Sonnet J, Shah A, Kawut SM, Bellamy SL, Localio AR, Christie JD.

Am J Transplant. 2015 Aug;15(8):2188-96. doi: 10.1111/ajt.13262. Epub 2015 Apr 15.

6.

Cognitive function, mental health, and health-related quality of life after lung transplantation.

Cohen DG, Christie JD, Anderson BJ, Diamond JM, Judy RP, Shah RJ, Cantu E, Bellamy SL, Blumenthal NP, Demissie E, Hopkins RO, Mikkelsen ME.

Ann Am Thorac Soc. 2014 May;11(4):522-30. doi: 10.1513/AnnalsATS.201311-388OC.

7.
8.

Genetic variation in the prostaglandin E2 pathway is associated with primary graft dysfunction.

Diamond JM, Akimova T, Kazi A, Shah RJ, Cantu E, Feng R, Levine MH, Kawut SM, Meyer NJ, Lee JC, Hancock WW, Aplenc R, Ware LB, Palmer SM, Bhorade S, Lama VN, Weinacker A, Orens J, Wille K, Crespo M, Lederer DJ, Arcasoy S, Demissie E, Christie JD; Lung Transplant Outcomes Group.

Am J Respir Crit Care Med. 2014 Mar 1;189(5):567-75. doi: 10.1164/rccm.201307-1283OC.

9.

Preoperative plasma club (clara) cell secretory protein levels are associated with primary graft dysfunction after lung transplantation.

Shah RJ, Wickersham N, Lederer DJ, Palmer SM, Cantu E, Diamond JM, Kawut SM, Lama VN, Bhorade S, Crespo M, Demissie E, Sonett J, Wille K, Orens J, Weinacker A, Shah P, Arcasoy S, Wilkes DS, Christie JD, Ware LB; Lung Transplant Outcomes Group.

Am J Transplant. 2014 Feb;14(2):446-52. doi: 10.1111/ajt.12541. Epub 2014 Jan 8.

10.

Latent class analysis identifies distinct phenotypes of primary graft dysfunction after lung transplantation.

Shah RJ, Diamond JM, Cantu E, Lee JC, Lederer DJ, Lama VN, Orens J, Weinacker A, Wilkes DS, Bhorade S, Wille KM, Ware LB, Palmer SM, Crespo M, Localio AR, Demissie E, Kawut SM, Bellamy SL, Christie JD.

Chest. 2013 Aug;144(2):616-622. doi: 10.1378/chest.12-1480.

11.

Clinical risk factors for primary graft dysfunction after lung transplantation.

Diamond JM, Lee JC, Kawut SM, Shah RJ, Localio AR, Bellamy SL, Lederer DJ, Cantu E, Kohl BA, Lama VN, Bhorade SM, Crespo M, Demissie E, Sonett J, Wille K, Orens J, Shah AS, Weinacker A, Arcasoy S, Shah PD, Wilkes DS, Ware LB, Palmer SM, Christie JD; Lung Transplant Outcomes Group.

Am J Respir Crit Care Med. 2013 Mar 1;187(5):527-34. doi: 10.1164/rccm.201210-1865OC. Epub 2013 Jan 10.

12.

Elevated plasma angiopoietin-2 levels and primary graft dysfunction after lung transplantation.

Diamond JM, Porteous MK, Cantu E, Meyer NJ, Shah RJ, Lederer DJ, Kawut SM, Lee J, Bellamy SL, Palmer SM, Lama VN, Bhorade SM, Crespo M, Demissie E, Wille K, Orens J, Shah PD, Weinacker A, Weill D, Arcasoy S, Wilkes DS, Ware LB, Christie JD; Lung Transplant Outcomes Group.

PLoS One. 2012;7(12):e51932. doi: 10.1371/journal.pone.0051932. Epub 2012 Dec 19.

13.

Plasma monocyte chemotactic protein-1 levels at 24 hours are a biomarker of primary graft dysfunction after lung transplantation.

Shah RJ, Diamond JM, Lederer DJ, Arcasoy SM, Cantu EM, Demissie EJ, Kawut SM, Kohl B, Lee JC, Sonett J, Christie JD, Ware LB.

Transl Res. 2012 Dec;160(6):435-42. doi: 10.1016/j.trsl.2012.08.003. Epub 2012 Sep 16.

14.

Variation in PTX3 is associated with primary graft dysfunction after lung transplantation.

Diamond JM, Meyer NJ, Feng R, Rushefski M, Lederer DJ, Kawut SM, Lee JC, Cantu E, Shah RJ, Lama VN, Bhorade S, Crespo M, Demissie E, Sonett J, Wille K, Orens J, Weinacker A, Weill D, Arcasoy S, Shah PD, Belperio JA, Wilkes D, Ware LB, Palmer SM, Christie JD; Lung Transplant Outcomes Group.

Am J Respir Crit Care Med. 2012 Sep 15;186(6):546-52. Epub 2012 Jul 19.

15.

A panel of lung injury biomarkers enhances the definition of primary graft dysfunction (PGD) after lung transplantation.

Shah RJ, Bellamy SL, Localio AR, Wickersham N, Diamond JM, Weinacker A, Lama VN, Bhorade S, Belperio JA, Crespo M, Demissie E, Kawut SM, Wille KM, Lederer DJ, Lee JC, Palmer SM, Orens J, Reynolds J, Shah A, Wilkes DS, Ware LB, Christie JD.

J Heart Lung Transplant. 2012 Sep;31(9):942-9. doi: 10.1016/j.healun.2012.05.001. Epub 2012 Jun 12.

16.

The adult respiratory distress syndrome cognitive outcomes study: long-term neuropsychological function in survivors of acute lung injury.

Mikkelsen ME, Christie JD, Lanken PN, Biester RC, Thompson BT, Bellamy SL, Localio AR, Demissie E, Hopkins RO, Angus DC.

Am J Respir Crit Care Med. 2012 Jun 15;185(12):1307-15. doi: 10.1164/rccm.201111-2025OC. Epub 2012 Apr 6.

17.

Elevated plasma long pentraxin-3 levels and primary graft dysfunction after lung transplantation for idiopathic pulmonary fibrosis.

Diamond JM, Lederer DJ, Kawut SM, Lee J, Ahya VN, Bellamy S, Palmer SM, Lama VN, Bhorade S, Crespo M, Demissie E, Sonett J, Wille K, Orens J, Shah PD, Weinacker A, Weill D, Kohl BA, Deutschman CC, Arcasoy S, Shah AS, Belperio JA, Wilkes D, Reynolds JM, Ware LB, Christie JD; Lung Transplant Outcomes Group.

Am J Transplant. 2011 Nov;11(11):2517-22. doi: 10.1111/j.1600-6143.2011.03702.x. Epub 2011 Aug 22.

18.

Effect of single vs bilateral lung transplantation on plasma surfactant protein D levels in idiopathic pulmonary fibrosis.

Sims MW, Beers MF, Ahya VN, Kawut SM, Sims KD, Lederer DJ, Palmer SM, Wille K, Lama VN, Shah PD, Orens JB, Bhorade S, Crespo M, Weinacker A, Demissie E, Bellamy S, Christie JD, Ware LB; Lung Transplant Outcomes Group.

Chest. 2011 Aug;140(2):489-496. doi: 10.1378/chest.10-2065. Epub 2011 Feb 24.

19.

Elevated plasma clara cell secretory protein concentration is associated with high-grade primary graft dysfunction.

Diamond JM, Kawut SM, Lederer DJ, Ahya VN, Kohl B, Sonett J, Palmer SM, Crespo M, Wille K, Lama VN, Shah PD, Orens J, Bhorade S, Weinacker A, Demissie E, Bellamy S, Christie JD, Ware LB; Lung Transplant Outcomes Group.

Am J Transplant. 2011 Mar;11(3):561-7. doi: 10.1111/j.1600-6143.2010.03431.x. Epub 2011 Feb 7.

20.

NF-κB1 inhibits TLR-induced IFN-β production in macrophages through TPL-2-dependent ERK activation.

Yang HT, Wang Y, Zhao X, Demissie E, Papoutsopoulou S, Mambole A, O'Garra A, Tomczak MF, Erdman SE, Fox JG, Ley SC, Horwitz BH.

J Immunol. 2011 Feb 15;186(4):1989-96. doi: 10.4049/jimmunol.1001003. Epub 2011 Jan 7.

21.

Elevated pulmonary artery pressure is a risk factor for primary graft dysfunction following lung transplantation for idiopathic pulmonary fibrosis.

Fang A, Studer S, Kawut SM, Ahya VN, Lee J, Wille K, Lama V, Ware L, Orens J, Weinacker A, Palmer SM, Crespo M, Lederer DJ, Deutschman CS, Kohl BA, Bellamy S, Demissie E, Christie JD; Lung Transplant Outcomes Group.

Chest. 2011 Apr;139(4):782-787. doi: 10.1378/chest.09-2806. Epub 2010 Sep 23.

22.

Construct validity of the definition of primary graft dysfunction after lung transplantation.

Christie JD, Bellamy S, Ware LB, Lederer D, Hadjiliadis D, Lee J, Robinson N, Localio AR, Wille K, Lama V, Palmer S, Orens J, Weinacker A, Crespo M, Demissie E, Kimmel SE, Kawut SM.

J Heart Lung Transplant. 2010 Nov;29(11):1231-9. doi: 10.1016/j.healun.2010.05.013. Epub 2010 Jul 22.

23.

Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction.

Christie JD, Shah CV, Kawut SM, Mangalmurti N, Lederer DJ, Sonett JR, Ahya VN, Palmer SM, Wille K, Lama V, Shah PD, Shah A, Weinacker A, Deutschman CS, Kohl BA, Demissie E, Bellamy S, Ware LB; Lung Transplant Outcomes Group.

Am J Respir Crit Care Med. 2009 Nov 15;180(10):1010-5. doi: 10.1164/rccm.200901-0118OC. Epub 2009 Aug 6.

24.

Soluble p-selectin and the risk of primary graft dysfunction after lung transplantation.

Kawut SM, Okun J, Shimbo D, Lederer DJ, De Andrade J, Lama V, Shah A, Milstone A, Ware LB, Weinacker A, Demissie E, Christie JD; Lung Transplant Outcomes Group.

Chest. 2009 Jul;136(1):237-244. doi: 10.1378/chest.08-2697. Epub 2009 Mar 2.

25.

Cognitive, mood and quality of life impairments in a select population of ARDS survivors.

Mikkelsen ME, Shull WH, Biester RC, Taichman DB, Lynch S, Demissie E, Hansen-Flaschen J, Christie JD.

Respirology. 2009 Jan;14(1):76-82. doi: 10.1111/j.1440-1843.2008.01419.x.

PMID:
19144052
26.

Plasma cytokines and chemokines in primary graft dysfunction post-lung transplantation.

Hoffman SA, Wang L, Shah CV, Ahya VN, Pochettino A, Olthoff K, Shaked A, Wille K, Lama VN, Milstone A, Ware LB, Orens J, Weinacker A, Demissie E, Bellamy S, Kawut SM, Hancock WW, Christie JD; Lung Transplant Outcomes Group.

Am J Transplant. 2009 Feb;9(2):389-96. doi: 10.1111/j.1600-6143.2008.02497.x. Epub 2008 Dec 15.

27.

Plasma intercellular adhesion molecule-1 and von Willebrand factor in primary graft dysfunction after lung transplantation.

Covarrubias M, Ware LB, Kawut SM, De Andrade J, Milstone A, Weinacker A, Orens J, Lama V, Wille K, Bellamy S, Shah C, Demissie E, Christie JD; Lung Transplant Outcomes Group.

Am J Transplant. 2007 Nov;7(11):2573-8. Epub 2007 Oct 1. Erratum in: Am J Transplant. 2008 Feb;8(2):469-70.

28.

Association of protein C and type 1 plasminogen activator inhibitor with primary graft dysfunction.

Christie JD, Robinson N, Ware LB, Plotnick M, De Andrade J, Lama V, Milstone A, Orens J, Weinacker A, Demissie E, Bellamy S, Kawut SM.

Am J Respir Crit Care Med. 2007 Jan 1;175(1):69-74. Epub 2006 Oct 5.

29.

The effect of primary graft dysfunction on survival after lung transplantation.

Christie JD, Kotloff RM, Ahya VN, Tino G, Pochettino A, Gaughan C, DeMissie E, Kimmel SE.

Am J Respir Crit Care Med. 2005 Jun 1;171(11):1312-6. Epub 2005 Mar 11.

30.

An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis.

Lewis JD, Lichtenstein GR, Stein RB, Deren JJ, Judge TA, Fogt F, Furth EE, Demissie EJ, Hurd LB, Su CG, Keilbaugh SA, Lazar MA, Wu GD.

Am J Gastroenterol. 2001 Dec;96(12):3323-8.

PMID:
11774944

Supplemental Content

Loading ...
Support Center